Skip to content

MEDVACON Articles

A Weak Investigation Does Not Just Explain The Event.
The Risk Is What Your Team Starts Accepting
Good Documentation Is Not More Documentation.
Incubators Build Momentum. Structure Protects the Progress.
A Strong BLA Will Not Save a Weak Operation
The Wrong Vendor Costs More Than the Invoice.
AI Is Not the Problem. Uncontrolled AI Is.
You Can Outsource Manufacturing. You Cannot Outsource Oversight.
To the Quality Professionals Holding the Line
You Raised the Capital. FDA Expects Control.
FDA’s March 2026 Draft Guidance Gives Drug CGMP Manufacturers a Clearer Framework for 483 Responses
FDA Has Already Completed 46 One Day Inspectional Assessments. Here Is What the Results Show.
FDA’s March 2026 Draft Guidance Gives Drug CGMP Manufacturers a Clearer Framework for 483 Responses
FDA Has Already Completed 46 One Day Inspectional Assessments